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This study proposes liposomes as a new tool for pretargeted radioimmunotherapy (RIT) 
in solid tumors. Tumor pretargeting is obtained by using a bispecific monoclonal antibody 
[BsmAb, anti-CEA × anti-DTPA-indium complex (DTPA–In)] and pegylated radioactive 
liposomes containing a lipid-hapten conjugate (DSPE–PEG–DTPA–In). In this work, 
the immunospecificity of tumor targeting is demonstrated both in vitro by fluorescence 
microscopy and in vivo by biodistribution studies.
Methods: Carcinoembryonic antigen (CEA)-expressing cells (LS174T) were used either 
in cell culture or as xenografts in nude mice. Doubly fluorescent liposomes or doubly 
radiolabeled liposomes were, respectively, used for in vitro and in vivo studies. In each 
case, a tracer of the lipid bilayer [rhodamine or indium-111 (111In)] and a tracer of the 
aqueous phase [fluorescein or iodine-125 (125I)] were present. The targeting of liposomes 
was assessed with BsmAb for active targeting or without for passive targeting.
results: Data obtained with the lipid bilayer tracer showed a fluorescent signal on cell 
membranes two to three times higher for active than for passive targeting. This immu-
nospecificity was confirmed in vivo with tumor uptake of 7.5 ± 2.4% ID/g (percentage 
of injected dose per gram of tissue) for active targeting versus 4.5 ± 0.45% ID/g for 
passive targeting (p = 0.03). Regarding the aqueous phase tracer, results are slightly 
more contrasted. In vitro, the fluorescent tracer seems to be released in the extracellular 
matrix, which can be correlated with the in vivo data. Indeed, the tumor uptake of 125I 
is lower than that of 111In: 5.1 ± 2.5% ID/g for active targeting and 2.7 ± 0.6% ID/g for 
passive targeting, but resulted in more favorable tumor/organs ratios.
conclusion: This work demonstrated the tumor targeting immunospecificity of DSPE–
PEG–DTPA–In liposomes by two different methods. This original and new approach 
suggests the potential of immunospecific targeting liposomes for the RIT of solid tumors.
Keywords: pegylated liposomes, radioimmunotherapy, bispecific antibody, pretargeting, solid tumors
November 2015 | Volume 2 | Article 832
Rauscher et al. Tumor Pretargeting of Radiolabeled and Functionalized Liposomes
Frontiers in Medicine | www.frontiersin.org
inTrODUcTiOn
The main purpose of radioimmunotherapy (RIT) is to kill cancer 
cells by immunospecific targeting radionuclides to specific 
antigens expressed at their surface. It has been demonstrated to 
be effective for the treatment of hematologic malignancies using 
directly radiolabeled antibodies targeting differentiation antigens, 
particularly in the treatment of malignant B cell lymphomas (1, 
2). But despite promising results, RIT is not as successful against 
solid malignancies, which are usually more radioresistant and 
less accessible to radiolabeled antibodies (3). Higher absorbed 
doses are necessary but administered activity is limited by normal 
organ toxicities (4).
In order to optimize the RIT of solid tumors, multi-step 
techniques, referred to as pretargeting, have been developed to 
improve target-to-normal tissues ratios and increase adminis-
tered activities while limiting healthy organ exposure. One of 
the pretargeting approaches is the affinity enhancement system 
(AES), which is based on bispecific monoclonal antibodies 
(BsmAb) and radiolabeled bivalent haptens (5). This approach has 
been extensively tested in the clinic and has shown an increase of 
overall survival of patients with progressive metastatic Medullary 
Thyroid Carcinoma, which provided the first evidence of survival 
improvement by RIT in solid tumors (6, 7). Nevertheless, the 
radiolabeled small molecular bivalent haptens are limited for 
RIT by the amount of activity they can carry in practice (8). Up 
to now, the specific activity of developed haptens labeled with 
available radionuclides does not exceed 100–150 MBq/nmol and 
even less for radionuclides with a long half-life, which limits the 
activity delivered to tumor cells. In this context, liposomes, which 
up to now have been especially developed for drug targeting, can 
represent a new and original method of radiotherapy of cancers. 
The development of imaging applications with radioactive 
liposomes is widely described (9, 10), but their advantages for 
carrying therapeutic radionuclides for cancer therapy could be 
further exploited.
This study aims at using immunospecific radiolabeled 
liposomes for RIT of solid tumors because they offer the pos-
sibility to carry high radionuclide activities, by radiolabeling their 
membrane, the inner aqueous phase or both. The potentially high 
number of radioactive atoms carried by each liposome should 
increase the dose delivered to the tumor and the avidity effect 
expected from the multiplicity of the liposome – target cell con-
nections should increase activity accretion in tumors, as with the 
AES that uses bivalent haptens to achieve cooperative binding to 
target cells. Finally, this liposome targeting approach will allow 
us to obtain an intermediate system between the direct targeting 
of radiolabeled mAb, which expose normal tissues, especially the 
red bone marrow, to excessive radiations and cause hematologic 
toxicities, and pretargeting which improves the tumor to back-
ground activity ratios but with a limitation in the activity that 
haptens can deliver to tumor cells.
In this paper, we aim to target tumors, by a two-step approach, 
using functionalized liposomes and a BsmAb (hMN14 ×  734) 
that recognizes on one arm the carcinoembryonic antigen (CEA) 
and on the other the DTPA–indium complex (DTPA–In). We 
used PEGylated liposomes that have been shown to be capable of 
very long circulation after intravenous injection with the hapten 
(DTPA–In) coupled at the end of the PEG chains (Figure  1). 
Surface plasmon resonance (SPR) was used previously to 
characterize specific interactions between antibodies and func-
tionalized liposomes in order to select the best formulation in 
terms of hapten presentation and density of PEG chains (11). The 
chosen formulation optimizes the antibody-hapten recognition 
by orienting the haptens away from the PEG structure (apparent 
dissociation constant KD = 6.3 × 10−9M), while keeping a long 
half-life in vivo (T1/2 = 12.5 h). The functionalized liposomes pre-
sent a large number of hapten molecules at their surface (around 
400), favorable pharmacokinetic parameters, and the possibility 
to be radiolabeled at high specific activities. For that, an original 
method to label preformed liposomes was previously developed, 
that could be extended to radionuclides of interest for therapy 
(iodine-131 or astatine-211). This technique is based on the use 
of radioiodinated Bolton-Hunter reagent (BH) and liposomes 
containing high concentration of arginine in order to radiolabel 
the inner aqueous core with 125I (12). The liposome membrane 
was also radiolabeled with 111In, using a chelating lipid inserted 
in the bilayer (DSPE–PEG–DTPA). The DTPA–Indium complex 
formed is the hapten specifically recognized by the 734 arm of the 
hMN14 × 734 bispecific antibody.
Then, specific tumor targeting experiments were performed 
in  vitro, by fluorescence microscopy, on CEA-expressing cells 
(LS734T), and in  vivo in nude mice xenografted with human 
colorectal adenocarcinoma cells (LS734T) to demonstrate the 
immunospecifity of pretargeting using functionalized liposomes 
and a bispecific antibody. Doubly fluorescent liposomes or doubly 
radiolabeled liposomes were, respectively, used for in vitro and 
in vivo studies. The double radiolabeling, with a tracer of the lipid 
bilayer (rhodamine or 111In) and a tracer of the aqueous phase 
FigUre 1 | Pretargeting of radiolabeled and functionalized liposomes 
using a bispecific monoclonal antibody (Bsmab) and a lipid-hapten 
conjugate.
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(fluorescein or 125I), was very useful to monitor the liposome 




N-succinimidyl-3-(4-hydoxyphenyl)-propionate (BH) was pur-
chased from Pierce Chemical Co. (Rockford, IL, USA). Arginine, 
chloramine T, fluorescein isothiocyanate (FITC), 1,2-distearoyl-
glycero-3-phosphocholine (DSPC), and cholesterol (Chol) were 
from Sigma-Aldrich (Steinheim, Germany).
1,2-Distearoyl-sn-glycerol-3-phophoethanolamine-
N-[Methoxy(Poly-ethylene glycol)-2000], M.W: 2805.54 
(DSPE–PEG2000) and 1,2-dioleoyl-sn-glycero-3-phosphoeth-
anolamine-N-(lissamine rhodamine B sulfonyl) M.W: 1301,7 
(DPPE-rhodamine) were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). DSPE–PEG2000–DTPA was synthesized 
by Ecole Nationale Supérieure de Chimie de Rennes (France).
Vesicle extruder and filter supports were purchased from 
Avanti Polar Lipids, Inc. Polycarbonate membranes for vesicle 
extrusion (100 nm pore size, Nucleopore) were from Whatman. 
All phospholipids were dissolved in 9:1 chloroform/methanol 
mixture (HPLC grade, Carlo Erba, and Fisher Scientific).
The anti-CEA/anti-DTPA–In (hMN14  ×  734) BsmAb was 
kindly provided by IBC Pharmaceuticals, Inc. (Morris Plains, 
NJ, USA).
Stable indium chloride (115In) was purchased from Sigma-
Aldrich and radioactive indium-111 chloride (111In) was 
purchased from Covidien (Petten, The Netherlands). 125I-iodide 
sodium was purchased from Perkin-Elmer (Wellesley, MA, USA).
liposome Preparation and 
characterization
DSPC/Chol/DSPE–PEG2000/DSPE–PEG2000–DTPA 
(64,5:30,5:3,5:1,5 molar ratio) or DSPC/Chol/DSPE–PEG2000/
DSPE–PEG2000–DTPA/DPPE–Rhodamine (64:30,5:3,5:1,5:0,5 
molar ratio) liposomes were prepared according to the lipid film 
hydration method described by Bangham (13).
Briefly, a total of 20 μmol of lipids (according to the molar 
ratios) was dissolved in chloroform/methanol (9:1 v/v) in a round 
bottom flask. A thin dry lipid film was obtained by solvent evapo-
ration using a rotary evaporator (Rotavapor®, Buchi). Hydration 
of the lipid film was performed by addition of 1 ml aqueous phase. 
The flask was vortexed vigorously and maintained above the 
transition temperature of lipids during 2 h in a rotary evaporator 
without vacuum at 74°C (gel-crystal transition temperature of 
DSPE). The final concentration of the liposome suspension was 
20 μmol of lipids/ml.
The aqueous phase was composed of 80 mM HEPES buffer 
pH 8 containing 80 mM arginine for radioactive liposomes and 
arginine 80 mM/HEPES 80 mM/FITC 20 mM for the fluorescent 
liposomes.
To obtain small and homogeneous vesicles, the liposome sus-
pension was extruded through Nucleopore polycarbonate filters 
using a manual thermostat-heated extrusion device (Avanti® 
Polar Lipids, Alabaster, AL, USA). The suspension was filtered 20 
times through filters with a pore size of 100 nm, at 74°C.
The size and the polydispersity of the vesicles were deter-
mined by granulometry by dynamic laser light-scattering 
measurements using a Malvern High Performance Particle 
Sizer (HPPS-ET, Instrument SA, UK). Measurements were per-
formed in triplicate after dilution of the suspension in filtered 
buffer.
Before liposome labeling, untrapped arginine was removed 
by FPLC (fast protein liquid chromatography) using a size-
exclusion Superdex® 200 column (Amersham pharmacia 
biotech, Orsay, France) eluted in 150 mmol/l, pH 5.6 phosphate 
buffer.
Radiolabeling Procedure
The aqueous phase radiolabeling was obtained by encapsulation 
of 125I using an active-loading method in which radioiodinated 
BH reagent reacts with pre-encapsulated arginine after crossing 
the lipid bilayer (12). The resulting positively charged conjugate 
(125I–BH–arginine) is then trapped inside the liposomes. In 
order to check the integrity of liposomes in vivo, they were also 
radiolabeled on the surface with 111In by complexation with 
DTPA coupled to phospholipids (14). Moreover, the DTPA–In 
complex constitutes also the hapten specifically recognized by the 
antibody 734.
Bolton–Hunter reagent was first radiolabeled with 125I by the 
chloramine T method and purified by solvent extraction (12). The 
organic solvent was then evaporated using a dry nitrogen stream.
Then, the double radiolabeling was obtained in one-step on 
preformed liposomes. Arginine-containing liposomes were added 
to the dry 125I–BH reagent (90 nmol of reagent for 1 μmol total 
lipids). Then, citrate buffer (100 mM, pH 5.0) was added, in order 
to obtain a final citrate concentration of 10 mM and a pH range 
of 5–6 required for 111In membrane radiolabeling. A mixture of 
a known amount of 115InCl3 with a trace activity of 111InCl3 (in 
HCl 0.06N) was added. Membrane radiolabeling was performed 
with a ratio of one indium (115In +  111In) molar equivalent per 
mole of available DTPA. The activity of 111In was used to deter-
mine the radiolabeling efficiency and the molar amount of 115In 
bound to DTPA that reflects the number of haptens expressed 
at the liposome surface. The liposomes were then incubated for 
30 min at 37°C with 125I–BH and 111In. At the end of incubation, 
a solution of EDTA was added to chelate free indium (10 EDTA 
molar equivalent per mole of indium) before purification by 
size-exclusion chromatography using a PD10 column (Sephadex 
G25, Bio-Rad). The labeling efficiencies were determined after 
purification by counting the different elution fractions for the two 
isotopes, with a γ-counter (Wallac 1480-Wizard®3, Perkin-Elmer, 
Paris, France).
Fluorescent Liposomes
To investigate the integrity of the DSPC/Chol/DSPE–
PEG2000/DSPE–PEG2000–DTPA/DPPE–R hodamine 
liposomes, the lipid bilayer of the fluorescent liposomes 
was labeled with Rhodamine and the aqueous phase with 
Fluorescein (Rho-labeled Fluo–Arg-loaded liposomes). 
Fluorescein was used in the form of isothiocyanate (FITC), 
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coupled beforehand with arginine to form fluorescein–argi-
nine (Fluo–Arg) conjugate, and encapsulated in a passive way 
during the preparation of liposomes, to a concentration of 
approximately 20 mM.
To be in the same conditions as with the radioactive liposomes 
and in order to form the DTPA–In hapten, functionalized 
liposomes were then saturated with non-radioactive 115In. This 
saturation was performed in acetate buffer 10 mM pH 5, by addi-
tion of indium chloride (HCl 0.06N) with 10 molar equivalents 
of 115In per mole of DTPA.
Fluorescence Microscopy
Cell Lines
The cell line was the same for in vitro and in vivo experiments. 
These human colorectal adenocarcinoma cells (LS174T) were 
acquired from American Type Culture Collection (USA) and 
expressed strongly the CEA antigen on their surface. They were 
cultured in medium suggested by RPMI 1640 (Gibco®) supple-
mented with glutamine 2 mM (Invitrogen, France) and 10% (v/v) 
fetal bovine serum (FBS) (Laboratory PAA, France). Cells were 
grown in tissue culture flasks to confluence at 37°C in humidified 
atmosphere with a partial pressure of CO2 of 5%.
Fluorescence microscopy studies were performed in time-
lapse to monitor the kinetics of interaction between cells and 
liposomes. LS174T cells (100,000/well) were washed once before 
to replace the culture medium by 300 μl of a diluted solution 
of BsmAb (10 μg/ml for specific targeting or 0 μg as control). 
After 1 h of incubation, cells were washed three times by 300 μl 
of culture medium. Rho-labeled Fluo–Arg-loaded functional-
ized liposomes were diluted (25 nmol/ml of lipids in RPMI) and 
300 μl were incubated with cells, which represents approximately 
750,000 liposomes per cell. Acquisitions were performed in time-
lapse after 15  min of incubation between liposome suspension 
and cells, during 6 h. To compare active (specific targeting with 
BsmAb) and passive targeting (without BsmAb), the fraction 
of liposomes bound to cells was quantified by measuring the 
fluorescence intensity of rhodamine.
Detection by Fluorescence Microscopy
Imaging of interactions between functionalized liposomes and 
cells was performed using a Nikon A1 Rsi confocal microscope 
(objectives Plan Apo ×60/1.4 and Plan Apo ×20/0.75). The 
microscope is adapted to the confocal imaging of fixed or living 
cells (control of the temperature or of the rate of CO2).
Fluorescence signals of fluoresceine and rhodamine were 
recorded after excitation by an argon laser and by a diode laser 
(respectively 488 and 561 nm exciter bandpass filters). The emit-
ted fluorescence was respectively collected at 525 and 595  nm 
(emitter bandpass filters). The images were acquired in a matrix 
size of 512 × 512 pixels and analyzed by the Fiji software and the 
NIS element (Nikon) software.
Biodistribution studies
Animal experiments were carried out in compliance with French 
regulation and approved by the Ethics Committee for animal 
experimentation  –  Région Pays de la Loire France (approval 
number: B44.565) according to the protocol CEEA.2012.171. 
NMRI-nu (nu/nu) mice were purchased from Janvier® (Le Genest 
Saint Isle, France). Mice were housed under standard conditions 
(standard diet and water ad libitum) and maintained in post-entry 
quarantine for 2 weeks before experiments.
Tumor targeting was performed in mice with CEA-
expressing subcutaneous tumor xenografts. Isolated human 
colorectal adenocarcinoma LS174T cells (2.5 ×  106) in 100 μl 
of sterile physiologic serum were injected into the right flank of 
NMRI-nu (nu/nu) mice. Biodistribution studies were performed 
at 10–15  days post-graft according to tumor growth (4–8  mm 
diameter tumors). Liposomes and antibodies were injected by 
intravenous bolus injection via the tail vein.
For the active targeting protocol, unlabeled anti-CEA/anti-
DTPA–In BsmAb (130 μg in 100 μl PBS, which corresponds to 
1.3  nmol) was injected first. Then, selected liposome formula-
tions were injected 24 h after the BsmAb. Mice received 100 μl 
of doubly radiolabeled liposomes containing 0.037–0.185 MBq 
(1–5 μCi) with 500 nmol of total lipids/mouse (100 nmol of func-
tionalized liposomes that corresponds to 0.5 nmol of hapten and 
400 nmol of non-functionalized liposomes co-injected to saturate 
the reticulo-endothelial system) (15). Control experiments were 
performed to determine the passive targeting of liposomes, with-
out injection of the BsmAb, under the same conditions.
Groups of four to five mice were used for each time point of 
biodistribution study: 3, 24, and 48  h post-injection. At each 
time point, blood samples were collected just before sacrifice and 
then tumor and normal organs were dissected. All samples were 
weighed and counted in a gamma counter calibrated for the two 
isotopes. Standards of the injected material were made in dupli-
cate and used to calculate the total injected dose and to correct 
for decay of the radioisotopes. The total radioactivity in the blood 
was determined by assuming that the total volume of blood was 
7% of the mice body weight (16). The results are expressed as a 
percentage of the total administered liposome dose accumulated 
per gram of tissues or remained in the blood (% DI/gram) ± SD.
The data from the biodistribution studies were compared using 
the non-parametric Wilcoxon’s test, due to the small numbers of 
animals, using p = 0.05.
resUlTs
liposomes Preparation and 
characterization
After filtration of the liposomes with the extruder, the mean 
size obtained for the different formulations was 105.5 ± 6.4 nm 
(polydispersity index <0.1).
The double radiolabeling of the liposomes, by 125I–BH encap-
sulation in the aqueous phase and by 111In chelation on DSPE–
PEG–DTPA at the surface, was performed by 30 min incubation 
at 37°C. Around 60% of encapsulation was obtained and the 
surface radiolabeling efficiency was above 77%. The number of 
DTPA–In on the liposome surface was estimated using a known 
amount of 115In and a tracer proportion of 111In to be around 
5 nmol/μmol of lipids.
FigUre 2 | Observation in time-lapse confocal microscopy (zoom ×20/640 μm × 640 μm): active targeting of doubly fluorescent functionalized 
liposomes on ls174T cells. (a) cells in brightfield, (B) FITC signal (ex/em 488/525 nm), (c) rhodamine signal (ex/em 561/595 nm). Scale bar: 100 μm.
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Fluorescence Microscopy
The kinetics of binding of the liposomes to the cells were assessed 
by time-lapse fluorescence microscopy (Figure  2). From the 
beginning of the acquisition and during 6  h, we observed an 
intense binding of rhodamine to cell membranes while no fluo-
rescence was observed inside the cells. The membrane-associated 
fluorescence was very intense and stable over time, but leakage 
of Fluo–Arg contained in the liposomes occurred when they 
interacted with the cell surface. Very quickly, a diffuse green 
fluorescence was observed in the extracellular area.
To demonstrate the immunospecificity of functionalized lipo-
some targeting to LS174T cells, acquisitions were performed by 
comparing the rhodamine signal bound to the membranes, with 
or without preincubation of cells with the bispecific antibody. In 
order to remove liposomes unbound to the cells, three washes 
were carried out by replacing the culture medium after 3  h of 
incubation with the liposomes. Signal obtained with rhodamine 
is represented in Figure 3, respectively for active targeting with 
antibody and passive targeting without antibody. These images 
represent the amount of fluorescence signal of five consecutive 
focal planes acquired along the Z axis and spaced with 2 μm.
Then, we selected two fields (zoom 1 and zoom 2) in which 
cells were counted in order to evaluate the fluorescence signal 
according to the number of cells. The intensity of the signal 
was thresholded by the Otsu algorithm (Table 1). For zoom 1, 
the mean fluorescence signal was 103 pixels per cell for active 
targeting and 29 pixels per cell for passive targeting, a bonding 
of Rho-labeled liposomes 3.6 times higher for active targeting. 
For zoom 2, where the difference of fluorescence was the lowest 
visually between passive and active targeting, the mean signal was 
66 and 31 pixels per cell, respectively, for the active and passive 
targeting, with a ratio of 2.1 for active targeting.
Biodistribution experiments
The best formulation of functionalized liposomes was defined in 
preliminary studies in terms of affinity to the BsmAb, tested by 
SPR, and in terms of pharmacokinetic parameters in  vivo (11, 
14). The chosen formulation (DSPC/Chol/DSPE–PEG2000/
DSPE–PEG2000–DTPA) showed the best affinity with 6.3  nM 
and favorable pharmacokinetic parameters (T1/2β ≅ 12.5 h). This 
formulation with DTPA at the end of the PEG chains orientates 
the hapten away from the PEG structure, in order to avoid steric 
hindrance.
In vivo biodistribution in tumor-xenografted nude mice is 
represented in Table 2. The activities in blood and in major 
organs are presented at 3, 24, and 48 h. The blood activities 
are quite comparable for the two radioisotopes that confirm 
the integrity of the circulating liposomes in vivo. Uptake in 
major organs was higher at 24  h with a higher accumula-
tion in liver, spleen, and kidneys, as widely described in the 
literature. Moreover, indium-labeled phospholipids remained 
in liver and spleen, which reflects the accumulation of radi-
olabeled phospholipids in catabolizing organs, whereas the 
radioiodinated BH-arginine is quickly eliminated from blood 
after liposome destruction. For example, the uptakes in liver, 
spleen and kidneys are respectively 16.5 ±  2.4, 34.3 ±  3.5, 
8.8 ± 1.7% ID/g with 111In and 4.1 ± 1.1, 9.1 ± 3.7, 2.1 ± 0.8% 
ID/g with125I.
Comparison of organ uptake for passive and active targeting 
is presented in Figure 4, for the two tracers. Results are presented 
at 24 h, when tumor uptake is highest. Biodistribution in healthy 
tissues was comparable for active and passive targeting, and no 
significant difference was shown for liver, spleen, kidneys and 
blood between passive and active targeting (p > 0.05).
Concerning tumor uptake, results showed a relatively impor-
tant passive targeting of the liposomes, in particular for the tracer 
of the lipid bilayer, with 4.4 ± 0.4% ID/g of tumor with 111In, and 
2.7 ± 0.6% ID/g with 125I. In spite of this high passive targeting, 
results demonstrated significant specific targeting, after BsmAb 
injection, with 7.5 ± 2.4% ID/g of tumor with 111In, and 5.1 ± 2.5% 
ID/g with 125I (p = 0.03), demonstrating the immunospecificity 
of the two-step targeting using functionalized liposomes and 
BsmAb.
On the other hand, it seemed interesting to take into account 
all the results of the biodistribution, by calculating the areas 
under the curve (AUC), which integrated the activities at 3, 24, 
and 48 h (Table 3). The values of AUC were calculated by the 
trapeze method from the mean activities for each time point. If 
we compare the results obtained with 111In (surface labeling) and 
125I (internal labeling), we can notice that for the healthy organs, 
the AUC is two to four times higher for the membrane labeling 
than for the internal phase labeling. Tumor/organs ratios are 0.4, 
FigUre 3 | comparison between passive (a,B) and active targeting (c,D) of fluorescent functionalized liposomes on ls174T cells, with cells in 
brightfield (a,c) and the corresponding rhodamine signal thresholded by the Otsu algorithm (B,D) (×20/2545 μm × 2545 μm).
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0.2, and 0.7 in 111In and 0.9, 0.4, and 1.6 in 125I, respectively, for 
liver, spleen, and kidneys. These ratios are more favorable for the 
internal labeling with values from 1.5 to 2 times superior to the 
ratios obtained for the membrane labeling.
DiscUssiOn
The originality of this study was to design a two-step targeting 
system with liposomes, similar to that used in AES, for the RIT 
TaBle 1 | Data obtained in vitro with rhodamine (lipid bilayer tracer) after quantification of the fluorescent signal on the ls174T cells membrane 
compared to the number of the cells for active targeting or passive targeting of fluorescent and functionalized liposomes.
Targeting 16 fields Zoom 1 Zoom 2
Fluorescence (pixels) cells Fluorescence (pixels) Pixels per cells cells Fluorescence (pixels) Pixels per cells
Passive targeting 107,498 622 17,929 29 583 17,929 31
Active targeting 331,454 424 43,881 103 343 22,646 66
Ratio 3:1 – – 3:6 – – 2:1
Zoom 1 and Zoom 2 correspond to the selected areas on Figure 3.
of solid tumors. Once the radiolabeling technique was finalized 
and the best formulation was selected by SPR (11), we were able 
to test these liposomes on a cellular model, using CEA-expressing 
LS174T cells, in order to characterize the specific interactions 
between liposomes and target cells.
In vitro, liposomes were surface-labeled with rhodamine and 
contained entrapped Fluo–Arg. Indeed, it seemed important 
in this work to monitor liposome integrity using a tracer of the 
membrane and a tracer encapsulated in the aqueous phase (17). 
FigUre 4 | Biodistribution of doubly radiolabeled liposomes (111in in black and 125i in gray) at 24 h in ls174T-xenografted nude mice for passive 
targeting or active targeting. Mice were injected i.v. with functionalized liposomes (0.5 nmol of hapten/mouse and 1–5 μCi for each radionuclide) without BsmAb 
injection (PT for Passive Targeting) or 24 h after BsmAb injection (AT for Active Targeting). The data are expressed as the percentage of total administered dose per 
gram of tissue (% ID/g, mean SD).
TaBle 2 | Biodistribution of functionalized DsPc/chol/DsPe–Peg2000/DsPe–Peg2000–DTPa–in (64.5:30.5:3.5:1.5) liposomes injected in ls174T-
xenografted nude mice (0.5 nmol of hapten/mouse and 1–5 μci for each radionuclide: 111in and 125i) 24 h after bispecific antibody (130 μg hMn14 × 734).
% iD/g 111in 125i
Tissue 3 h (n = 4) 24 h (n = 4) 48 h (n = 4) 3 h (n = 4) 24 h (n = 4) 48 h (n = 4)
Tumor 3.6 ± 0.2 7.5 ± 2.4 5.6 ± 1.1 2.5 ± 1.0 5.1 ± 2.5 1.2 ± 0.3
Blood 20.3 ± 2.5 2.9 ± 1.0 0.5 ± 0.2 18.0 ± 3.5 2.1 ± 0.6 0.3 ± 0.1
Liver 11.4 ± 1.1 16.5 ± 2.4 15.3 ± 2.0 6.7 ± 1.3 4.1 ± 1.0 0.5 ± 0.1
Kidneys 6.9 ± 1.0 8.8 ± 1.7 7.6 ± 2.4 3.5 ± 0.7 2.1 ± 0.8 1.1 ± 0.3
Intestine 2.8 ± 1.0 2.7 ± 1.5 3.0 ± 0.6 2.0 ± 0.6 1.4 ± 0.7 0.5 ± 0.2
Lung 7.0 ± 1.1 2.0 ± 0.7 1.3 ± 0.3 5.1 ± 1.4 1.4 ± 0.6 0.25 ± 0.08
Muscle 0.6 ± 0.1 0.5 ± 0.1 0.42 ± 0.09 0.35 ± 0.07 0.16 ± 0.05 0.04 ± 0.01
Spleen 21.2 ± 1.9 34.3 ± 3.5 29.4 ± 2.4 8.7 ± 0.3 9.1 ± 3.7 4.3 ± 2.2
Skin 1.8 ± 0.4 4.2 ± 1.6 4.1 ± 0.5 1.0 ± 0.3 1.6 ± 0.9 0.6 ± 0.1
Brain 1.1 ± 0.4 0.16 ± 0.04 0.08 ± 0.01 0.8 ± 0.3 0.12 ± 0.04 0.014 ± 0.003
Heart 4.8 ± 2.2 2.2 ± 0.7 2.0 ± 0.4 4.8 ± 1.8 1.3 ± 0.4 0.6 ± 0.2
Bone 3.4 ± 0.7 2.0 ± 0.6 1.6 ± 0.2 2.3 ± 0.5 0.6 ± 0.3 0.13 ± 0.04
Stomach 0.8 ± 0.1 0.8 ± 0.5 0.6 ± 0.4 0.66 ± 0.09 0.5 ± 0.3 0.18 ± 0.09
The data are expressed as the percentage of total administered dose per gram of tissue (% ID/g, mean ± SD).
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To observe the kinetics of interaction of the liposomes with 
the cells, time-lapse fluorescence microscopy was used. The 
incubation of LS174T cells with Rho-labeled Fluo–Arg-loaded 
functionalized liposomes did not result in a co-localization of 
the fluorescent tracers. An intense fixation of the rhodamine on 
cell membranes was observed during 6  h, while the Fluo–Arg 
was totally released (diffuse green fluorescence in the extracel-
lular medium). This leakage was attributed to the interaction of 
the cell surface proteins with the liposome bilayer, and depends 
on the liposome formulation, in particular when the Chol lipid 
proportion increased from 30 to 40 moles% of lipids (18).
In this work, despite a supplementation of the medium by 10% 
of FBS, non-specific binding was observed after incubating the cells 
and liposomes, without BsmAb (passive targeting). Nevertheless, 
the rhodamine fluorescence signal associated to the liposomes 
was higher in the case of active targeting compared to passive 
targeting with a ratio of 3:1 obtained by signal quantification.
TaBle 3 | areas under the curve (aUc) and tumor/organs ratios (T/O) 
calculated for the main organs (% iD/g) after biodistribution (3, 24, and 
48 h) of functionalized liposomes administered i.v. 24 h after Bsmab 
injection in ls174T-xenografted nude mice.
111in 125i
aUc T/O aUc T/O
Tumor 278 1.0 158 1.0
Blood 437 0.6 329 0.5
Liver 692 0.4 178 0.9
Kidneys 371 0.7 103 1.6
Spleen 1379 0.2 361 0.4
In second part, the ability of functionalized and pegylated 
liposomes to target CEA-expressing tumors, was tested in xeno-
grafted nude mice, with the two-step targeting system using the 
hMN14 × 734 BsmAb. The double radiolabeling proved of real 
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interest to compare the behavior of the radioactivity encapsulated 
in the aqueous phase and that carried by radiolabeled phospho-
lipids in the lipid bilayer.
Blood levels of the two tracers remained the same at differ-
ent times after injection, thus demonstrating the stability of 
the liposomes in the circulation. By contrast, phospholipids 
radiolabeled with residualizing 111In accumulate in catabolizing 
organs, with a prominent uptake in liver and spleen, whereas 
encapsulated-125I–BH–arginine was quickly eliminated in urine 
after liposome destruction (14). The maximum tumor uptake was 
observed at 24 h. At this time, tumor/organ ratios were superior 
to 1 for 125I, except for the spleen. For liver, spleen and kidneys, 
ratios were, respectively, 1.24, 0.56, and 2.42 for 125I and 0.45, 0.22, 
and 0.85 for 111In.
In spite of relatively high tumor uptake with passive targeting, 
results demonstrated significant specific targeting, after BsmAb 
injection, with 7.5 ± 2.4% ID/g of tumor with 111In, and 5.1 ± 2.5% 
ID/g with 125I. The lower tumor uptake obtained with 125I confirms 
in vitro results. A release of the content was effectively observed 
by fluorescence microscopy, as the liposomes interacted with the 
cellular target. Pegylation of the liposomes provides a long half-
life, which allows them to reach the tumor, but after interaction 
with the target cells, the encapsulated-tracer (125I–BH–arginine or 
Fluo–Arg) is released in part. However, encapsulating the radio-
activity in the aqueous phase favors a more rapid elimination of 
the hydrophilic radiolabeled compound and reduces the healthy 
organs irradiation.
If specific targeting of functionalized liposomes has been 
documented extensively in vitro (17, 19, 20), most of the in vivo 
targeting experiments described in the literature do not show 
significant differences between passive and active targeting. 
For example, Petersen et  al. described a tumor targeting with 
a somatostatine analog (TATE)-functionalized liposomes. 
Results obtained for specific targeting were 5.2  ±  0.5% ID/g 
versus 5.5 ± 0.3% ID/g with non-specific control liposomes (21). 
Similarly, no difference in tumor accumulation was obtained 
using folate-functionalized liposomes to target different tumors 
which overexpressed folate receptors (22). In this particular 
case, it was shown that despite the enhanced affinity of specific 
liposomes to tumor cells, tumor uptake was not improved 
because of a rapid elimination of the functionalized liposomes 
by the liver. By using immunoliposomes, carrying monoclonal 
antibodies or their fragments, specific targeting does not improve 
tumor accumulation, essentially resulting from the well known 
enhanced permeability and retention (EPR) effect (23), but nev-
ertheless authors conclude that immunoliposomes can increase 
interaction with the cells, and notably by internalization (24). 
On the other hand, no significant difference was demonstrated 
between passive targeting and active targeting, when the target 
antigen is internalizing, either with immunoliposomes or with 
pretargeting (25). The pretargeting system used in our study is 
based on the recognition of CEA antigen, widely known to be 
very slowly internalized and not to promote the endocytosis of 
liposomes (26, 27). In this system, a specific tumor targeting, 
in vitro and in vivo, was thus demonstrated with the pretargeted 
functionalized liposomes.
cOnclUsiOn
Specific targeting of liposomes is difficult to demonstrate in vivo 
because they accumulate in tumors passively through the EPR 
effect. Nevertheless, this study shows the interest of a two-step 
targeting, using functionalized liposomes and BsmAb, of a non-
internalizing antigen. Indeed, the specific targeting observed 
in vitro, on CEA-expressing cells, is confirmed in vivo by a signifi-
cant increase of tumor uptake in vivo, which was not previously 
described in the literature. The immunospecificity of targeting is 
indeed often offset by the EPR effect and by the rapid elimination 
of the immunoliposomes or by the internalization of the antibody 
used in the pretargeting system. In this work, the pretargeting 
approach allowed us to use stable unlabeled BsmAb and liposomes 
tailored for optimal in vivo behavior and suitable for extempora-
neous radiolabeling. This original and new approach suggests a 
potential for immunospecific liposome pretargeting for RIT.
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